Search Bar & Filters
Found 29 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are studying the effects of anifrolumab, given as a 120 mg subcutaneous injection once weekly, for patients with systemic lupus erythematosus SLE who have not used immunosuppressants or biologic therapies before. The study aims to understand clinical outcomes like remission rates and the ability to taper off glucocorticoids GCs safely in patients not meeting low disease activity status at enrollment. Participants will receive anifrolumab injections weekly for 52 weeks, alongside their usual antimalarial treatment, with or without glucocorticoids. The study includes a 35-day screening period before treatment starts. Glucocorticoid doses may be increased during the first 4 weeks if needed, then tapered gradually between weeks 5 and 40 following a specific protocol. Those achieving remission can attempt complete withdrawal of glucocorticoids after tapering. After week 41, glucocorticoid doses will remain stable. Safety follow-up occurs 12 weeks after the last dose for participants who stop treatment after week 52. Participants will undergo regular assessments throughout the study to evaluate disease activity, remission status, glucocorticoid use, and quality of life. Researchers will monitor various outcomes, including time spent in remission, flare occurrences, skin and joint symptoms, and adverse events. The total participation time is approximately 69 weeks, including screening, treatment, and safety follow-up, with detailed tracking of glucocorticoid use and disease status at multiple time points.
Actively Recruiting
Researchers are evaluating the medicine BI 3000202 in adults with moderate to severe systemic lupus erythematosus SLE to find out if it helps manage the condition. This phase II study randomly assigns participants to one of five groups, including four different doses of BI 3000202 and one placebo group. The goal is to determine the best dose while monitoring the safety and effects of the medicine. Participants take their assigned tablets daily for one year while continuing their regular SLE treatments. The study involves a randomized, placebo-controlled, double-blind design with parallel groups. Four groups receive varying doses of BI 3000202, and one group receives placebo tablets that look the same but contain no medicine. During the study, participants visit the study site regularly for health checks, monitoring of any side effects, and assessments of their disease activity using tools like the Systemic Lupus Erythematosus Responder Index. The study lasts a bit longer than one year, allowing thorough evaluation of treatment effects and safety. Researchers compare results among the groups to understand the medicines impact on SLE.
Actively Recruiting
Researchers are studying whether the medicine nerandomilast can help slow lung changes in people aged 40 or older who have a family history of pulmonary fibrosis. This condition causes scarring in the lungs, making breathing difficult, and early lung changes detected by scans may lead to this scarring. The study aims to find ways to prevent lung fibrosis from getting worse in those at higher risk due to family history. Participants are randomly assigned to two groups one takes nerandomilast tablets and the other takes placebo tablets that look the same but contain no medicine. They take one tablet twice daily for about 2 to 3 years. The chance of receiving nerandomilast is 3 in 5. The study includes frequent visits during the first 2 years, approximately every 3 months, then visits every 6 months in the third year, along with phone calls every 3 months during that last year. During the study, doctors regularly check lung function and perform chest scans to monitor lung changes and see if nerandomilast affects the condition. They also track participants health and any side effects. The main measure is the time until lung changes worsen over the full trial period. The total participation time is about 2 to 3 years with ongoing assessments throughout.
Actively Recruiting
Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.
Actively Recruiting
Researchers are evaluating two different strategies to prevent heart damage in elderly cancer patients undergoing anti-tumoral treatment. This randomized, multicenter, open-label clinical trial compares an intensive cardiovascular monitoring approach involving cardio-onco-hematology teams with the current standard practice where cardiac care is based on the onco-hematologists criteria. The main goal is to see if the primary prevention strategy reduces overall death rates compared to the secondary prevention approach. Participants will be assigned to either the primary prevention group receiving intensive cardiovascular monitoring or the secondary prevention group following usual clinical practice. The intensive monitoring includes evaluations before chemotherapy, at three and six months, then annually for five years, comprising physical exams, EKG, echocardiograms, biomarkers, counseling on heart health, and care coordination by specialized teams. The secondary prevention group will have similar scheduled visits but cardiac care based only on the onco-hematologists decisions. During the study, participants will undergo assessments including physical exams, heart tests, quality of life questionnaires, and performance status evaluations at set intervals over five years. Researchers will track outcomes such as all-cause mortality, cancer and cardiovascular deaths, hospitalizations due to heart or cancer complications, tumor progression, and cost-effectiveness. These measures will be evaluated at two and five years to understand the impact of the prevention strategies.
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
Researchers are evaluating treatment options for patients with coronary artery disease caused by calcified nodules. This international, multicenter, open-label randomized trial compares two approaches after using intravascular lithotripsy to modify the plaque drug eluting balloons DEB and drug eluting stents DES. The study aims to assess the safety and effectiveness of these treatments and to determine if DEB is at least as good or possibly better than DES in this setting. Participants undergo a percutaneous coronary intervention PCI involving intravascular lithotripsy to break up the calcified plaques. They are then randomly assigned to receive either a drug eluting balloon or a drug eluting stent to treat the lesion. This leave-nothing-behind strategy is studied for its potential to reduce risks related to stent placement. The trial follows patients for outcomes up to 24 months, with key measurements at 9 and 12 months. During the study, participants receive imaging to confirm the calcified nodule lesion and have follow-up angiographic assessments. Researchers monitor outcomes including late lumen loss and net lumen gain at 9 months, as well as safety events such as vessel dissection, perforation, thrombosis, and major adverse cardiac events up to 24 months. The trial also tracks additional measures like minimal lumen diameter and target lesion revascularization. Participation lasts through treatment and extended follow-up to evaluate both effectiveness and safety.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
Researchers are evaluating two home-based digital cognitive training programs for cancer survivors who experience cognitive difficulties after chemotherapy. This study aims to compare the usability and effectiveness of a computerized cognitive intervention BrainHQ and a virtual reality cognitive intervention Enhance VR as part of an early rehabilitation protocol following cancer treatment. The goal is to understand which intervention is best accepted and most effective in improving cognitive function and quality of life. Participants will be randomly assigned to one of three groups the BrainHQ computerized training, the Enhance VR virtual reality training, or a control group receiving usual care without cognitive intervention. Both interventions involve cognitive exercises targeting attention, memory, processing speed, and other functions, conducted remotely for 10 weeks. BrainHQ sessions are about 30 minutes each, five times per week, while Enhance VR sessions are 30 minutes, four times per week. Weekly psychologist supervision will support participants during the training period. Participants are assessed before starting the intervention, after completing the 10-week program, and again one year later to examine lasting effects. Assessments include cognitive tests, quality of life questionnaires, and adherence monitoring. The study also explores patient satisfaction, usability of the interventions, and an exploratory cost analysis. Overall, this research seeks to help cancer survivors regain their cognitive abilities and improve their return to work, family, and social activities.
1-10 of 29
1